drugset / Trial / NCT02063204

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

NCT02063204

Phase 1 Completed 24 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelBasic science

Summary

A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244, ARRY-142886) in subjects with renal impairment and healthy subjects

Timeline

Start
2014-03
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Selumetinib Small molecule 50 mg Oral

Indications